Goldman Sachs downgraded Dynavax to Sell, citing increased competition in the shingles vaccine market and uncertainty over hepatitis B revaccination demand.
Two sexually transmitted infections are spreading faster than ever. Our expert guide tells you everything you need to know, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback